Registered human trialNot yet recruitingNo efficacy data yet

Phase 1/2

ReINFORCE

Clemastine • acute demyelinating lesions

Compound / intervention: Clemastine • acute demyelinating lesions
Mechanism: Clemastine; muscarinic-receptor antagonism
Development stage: Phase 1/2
Status: Not yet recruiting • scheduled start 15 Sep 2026
Population / locations: Site: UCSF, US • not yet recruiting
Evidence level: Human Phase 1/2 • no results

Next substantive checkpoint

Recruitment opening and multiparametric MRI readouts for myelin repair

University / investigatorOpen source ↗Last checked: 16 Sep 2026

Related substantive developments

No separate substantive update is currently linked.